After the regulator’s rejection of two rivals, GlaxoSmithKline’s daprodustat could be the first in a new class of oral anemia drugs approved in the US, but concerns about class safety may mean its use is limited.
The company confirmed on 19 April that the US Food and Drug Administration had accepted the filing of the oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the potential
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?